Juergen brings more than 25 years of drug research and development experience to his role as co-founder and chief executive officer at Nova Mentis Pharma. Prior to Nova Mentis Pharma Juergen founded and has been leading Scientific Research Partners as chief executive officer since 2012. He has also served in various leadership positions at the Bill & Melinda Gates Foundation, Airway Therapeutics, Nektar, Celera, Theravance, Genentech, and Xoma where he has supported the successful filing of multiple INDs. Furthermore, he gathered extensive experience in pulmonary models and drug delivery for multiple disease areas and was furthermore instrumental in the strategic planning and tactical execution of functional and corporate objectives. Juergen has also co-authored over 45 publications and is also an inventor on a US patent.
Dr. Jennifer Riggs-Sauthier is a strategic leader with 23 years’ experience in drug discovery and development within the pharmaceutical industry. She is committed to focused medicinal chemistry and drug discovery with an emphasis on structure-guided drug design and critical thinking. Her specialties include the design, synthesis, and pre-clinical development, through IND-enabling, of both small molecule and protein drugs as well as polymer drug conjugates across various therapeutic areas (pain, oncology, metabolic diseases, inflammation, immunotherapy, infectious and rare diseases). Her accomplishments include the generation of 14 development candidates, 10 investigational new drug (IND) applications leading to 2 marketed medicines (Movantik, Adynovate) and 1 Phase 3 NDA (NKTR-181), > 42 patents, over 30 peer reviewed publications, and project team lead of partnered pre-clinical projects with Top 5 Pharmaceutical Companies (AstraZeneca, GSK, Pfizer, and BMS).
Dr. Hamlin is a professor, researcher and Diplomate of the American College of Veterinary Internal Medicine and Cardiology, and his contributions to cardiovascular physiology have greatly influenced modern veterinary and human medicine. His work on the canine heart and subsequent research in the treatment of heart disease has benefited both man and animal. He is the author of approximately 300 peer-reviewed articles and serves on the editorial board of several veterinary and scientific journals. Dr. Hamlin is an internationally recognized clinician, scholar and lecturer in cardiology, physiology and pharmacology. He is a Director at the Q-Test Labs, a preclinical cardiovascular laboratory that supports the development of new cardiovascular therapies for animals and humans. Dr. Hamlin received his bachelor’s degree in agriculture, his doctorate of veterinary medicine and additional master’s and doctorate degrees, all from Ohio State. Dr. Hamlin joined the Ohio State faculty in 1960, and served as a research fellow at the Cleveland Area Heart Association, the Central Ohio Heart Association and the National Institutes of Health.
Nova Mentis Pharma 